A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers.

Trial Profile

A Phase 2 Randomized Study of Tarceva (Erlotinib) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With Newly Diagnosed Advanced Non-Small Cell Lung Cancer Who Have Tumors With EGFR Protein Overexpression and/or Increased EGFR Gene Copy Numbers.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2012

At a glance

  • Drugs Carboplatin; Erlotinib; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors OSI Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 08 Aug 2011 Results published in the Journal of Clinical Oncology.
    • 30 Jun 2010 Primary endpoint 'Progression-free-survival-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top